We are proud to say that we have a number of innovative private investors and leading venture capital firms as our partners.
BioMedPartners AG is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. BioMedPartners focuses on pharmaceuticals, biotechnology, diagnostics and medical technology. The team consists of experienced investment professionals with extensive expertise in investing and building healthcare companies, supported by a dedicated team of seasoned senior scientific and business advisors. The team also has access to a broad network within academia, finance and industry.
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. With over €150 million under management in two funds, Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financing rounds. The investment strategy is focused on four areas – therapeutics, medical devices, diagnostics and novel food applications – and invests in European projects in all stages of development.
Seventure Partners is a leading venture capital firm in Europe, and invests in innovative businesses with high growth potential in digital technologies in France and Germany, and in life sciences across Europe, with currently over €500m in assets under management.
In life sciences, the areas of focus include: biotechnology and pharmaceuticals; connected health and medtech; industrial biotechnology and cleantech; and the microbiome, lifestyle healthcare, personalised medicine, nutrition and food. Seventure Partners invests in diagnostics, biomarkers, drug delivery systems, and services. Seventure is a subsidiary of Natixis, the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.
Peppermint VenturePartners (PVP) is an independent Venture Capital Firm managing more than €50 million through two funds, Peppermint VC-1 and the recently established Peppermint Charité Biomedical Fund 1 (CBF-1). Through its established collaboration with the Berlin Charité University , PVP has access to the proprietary network and evaluation platform of one of the largest medical schools in Europe and to its international partners.
PVP’s goal is to invest in young healthcare companies in Germany and across Europe that have demonstrated proof-of-concept for their technology, product or services. Potential investment targets include medical device, diagnostics and services companies.
IBB Beteiligungsgesellschaft provides venture capital to innovative Berlin enterprises. The funds are used primarily for the development and market launch of innovative products or services, as well as for business concepts of creative industries. Currently two of the funds managed by the IBB Beteiligungsgesellschaft are in the investment phase, the VC Fonds Technologie Berlin with a fund size of € 52 million and the VC Fonds Berlin Kreativwirtschaft Berlin with a fund size of € 30 million. Both VC funds are financed by means of the Investitionsbank Berlin (IBB) and the European Fund for Regional Development (EFRE) administered by the State Berlin.
KfW finances projects at German and European companies. KfW ERP-Startfonds support start up companies through investment capital, with KfW participating alongside other investors.
High Tech Gründer Fonds invests in young, high potential high-tech start-ups, providing seed financing to enable start-ups to take an from concept to market launch. Investors in this public/private partnership include the Federal Ministry of Economics and Technology, the KfW Banking Group, as well as thirteen industrial groups: ALTANA, BASF, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom,Evonik, Qiagen, RWE Innogy, Tengelmann and Carl Zeiss.
Berlin-based Ventegis Capital AG has almost two decades of expereince in venture capital, along with contacts across Europe. Ventegis’ funds focus on innovative, fast-growing early stage and expansion companies in cleantech and medtech/diagnostics. Ventegis is an integrated part of Berliner Effektengesellschaft AG (BEG AG) which operates as a financial holding for a number of companies in the financial sector.